Q1 2018 EPS Estimates for Agios Pharmaceuticals Inc (AGIO) Raised by Analyst

Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Equities research analysts at Leerink Swann upped their Q1 2018 earnings estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Thursday. Leerink Swann analyst M. Schmidt now forecasts that the biopharmaceutical company will earn ($1.61) per share for the quarter, up from their previous forecast of ($1.67). Leerink Swann also issued estimates for Agios Pharmaceuticals’ Q2 2018 earnings at ($1.44) EPS, Q3 2018 earnings at ($1.42) EPS, Q4 2018 earnings at ($1.34) EPS, FY2018 earnings at ($5.78) EPS, FY2019 earnings at ($4.41) EPS and FY2020 earnings at ($2.88) EPS.

AGIO has been the subject of a number of other research reports. Credit Suisse Group upped their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. Oppenheimer lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 14th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 target price for the company in a research report on Tuesday, January 16th. Canaccord Genuity set a $90.00 target price on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Finally, ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Agios Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $85.50.

Agios Pharmaceuticals (NASDAQ AGIO) opened at $77.53 on Monday. Agios Pharmaceuticals has a 12-month low of $45.11 and a 12-month high of $82.96. The firm has a market cap of $4,454.29, a price-to-earnings ratio of -11.50 and a beta of 2.12.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The company had revenue of $9.80 million for the quarter, compared to the consensus estimate of $12.65 million. During the same quarter in the prior year, the company posted ($1.34) EPS. Agios Pharmaceuticals’s revenue was down 56.7% compared to the same quarter last year.

Several institutional investors and hedge funds have recently made changes to their positions in AGIO. Alkeon Capital Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the third quarter valued at $30,489,000. UBS Asset Management Americas Inc. raised its stake in shares of Agios Pharmaceuticals by 965.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 345,284 shares of the biopharmaceutical company’s stock valued at $19,740,000 after acquiring an additional 312,878 shares during the period. First Trust Advisors LP raised its stake in shares of Agios Pharmaceuticals by 26.3% in the fourth quarter. First Trust Advisors LP now owns 813,647 shares of the biopharmaceutical company’s stock valued at $46,516,000 after acquiring an additional 169,331 shares during the period. OppenheimerFunds Inc. raised its stake in shares of Agios Pharmaceuticals by 679.7% in the fourth quarter. OppenheimerFunds Inc. now owns 142,283 shares of the biopharmaceutical company’s stock valued at $8,134,000 after acquiring an additional 124,035 shares during the period. Finally, Lord Abbett & CO. LLC raised its stake in shares of Agios Pharmaceuticals by 81.5% in the second quarter. Lord Abbett & CO. LLC now owns 266,910 shares of the biopharmaceutical company’s stock valued at $13,733,000 after acquiring an additional 119,836 shares during the period. 84.04% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Steven L. Hoerter sold 25,000 shares of the company’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $74.83, for a total transaction of $1,870,750.00. Following the sale, the insider now owns 25,000 shares of the company’s stock, valued at $1,870,750. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Christopher Bowden sold 2,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $77.65, for a total transaction of $155,300.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 185,114 shares of company stock worth $14,021,325. 5.43% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Q1 2018 EPS Estimates for Agios Pharmaceuticals Inc (AGIO) Raised by Analyst” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/21/q1-2018-eps-estimates-for-agios-pharmaceuticals-inc-agio-raised-by-analyst.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply